期刊文献+

不同抗苗勒管激素水平的多囊卵巢综合征患者的IVF-ET/ICSI结局分析 被引量:10

Analysis of IVF-ET clinical outcomes in patients with polycystic ovary syndrome with different anti-mullerian hormone Levels
原文传递
导出
摘要 目的探讨PCOS患者血清AMH水平与其内分泌及IVF-ET/ICSI临床结局关系,并评估AMH与这些指标的相关性。方法回顾性分析111例PCOS患者的一般情况及IVF-ET/ICSI临床结局。根据AMH水平将其分为A(AMH≤5.66),B(5.66<AMH≤7.94),C(7.94<AMH≤11.87),D(11.87<AMH)四组,并比较四组间的内分泌及IVF-ET/ICSI临床结局相关指标的差异性。结果各组在年龄、BMI、bT、bLH、临床妊娠率、活产率无上无统计学差异(P>0.05)。但在较高AMH水平下,bFSH、AFC、Gn量、HCG日E2水平、获卵数、优胚数存在差异(P<0.05)。进行相关分析时,发现bT、bE2、临床妊娠率、活产率无相关关系(P>0.05),而AMH与年龄、BMI、FSH、Gn量成负相关(P<0.05),与LH、HCG日E2、AFC、获卵数成正相关(P<0.05)。结论血清AMH水平对PCOS患者IVF-ET/ICSI临床结局无直接相关性。 Objective: Investigating the relationship between serum AMH levels and clinical outcomes of endocrine parameters and IVF-ET/ICSI in patients with PCOS, and evaluating the association of AMH with these indicators. Methods: A retrospective analysis of 111 cases of PCOS patients and IVF-ET/ICSI chnical outcomes. According to AMH levels, the study divide it into four groups: A (AMH≤5.66) , B (5.66〈AMH ≤7.94) , C (7.94〈AMH≤ll.87) , and D (ll.87〈AMH) , and compare the endocrine parameters and IVF-ET/ICSI clinical outcomes between the four groups. Results: There was no significant difference in age, BMI, bT, bLH, clinical pregnancy rate, and live birth rate among the groups (P〉0.05) . However, at higher AMH levels, there were differences in bFSH, AFC, Gn levels, HCG day Ez levels, number of retrieved eggs, and number of embryos (P〈0.05) . When correlation analysis was performed, there was no correlation among bT, bE2, clinical pregnancy rate, and live birth rate (P〉0.05) , but AMH was negatively correlated with age, BMI, FSH, and Gn (P〈0.05) , and positively correlated with LH, HCG E2, AFC, and the number of retrieved eggs (P〈0.05) . Conclusion: Serum AMH levels have no direct correlation with the IVF-ET/ICSI clinical outcomes in patients with polycystic ovary syndrome.
作者 殷露 穆杨 黄小烜 尹太郎 胡雪 杨菁 YIN Lu;MU Yang;HUANG Xiao-yuan;YIN Tai-lang;HU Xue;YANG Jing(Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处 《中国优生与遗传杂志》 2018年第11期116-119,82,共5页 Chinese Journal of Birth Health & Heredity
关键词 多囊卵巢综合征(PCOS) 抗苗勒管激素AMH 体外受精(IVF) Polycystic ovary syndrome Anti-Mullerian hormone IVF
  • 相关文献

参考文献4

二级参考文献134

  • 1杜乃立,戚文航.外周多巴胺受体激动剂及其应用[J].国外医学(心血管疾病分册),2000,27(3):131-133. 被引量:7
  • 2史樱,金婧.达英-35联合二甲双胍治疗多囊卵巢综合征的疗效观察[J].中国妇幼保健,2007,22(24):3449-3451. 被引量:27
  • 3Huime JA, Lambalk CB, van Loenen AC, et al. Contemporarypharmacological manipulation in assisted reproduction. Drugs,2004,64(3):297-322. 被引量:1
  • 4The Practice Committee of the American Society for Repro-ductive Medicine. Use of clomiphene citrate in infertilewomen: a committee opinion. Fertil Steril, 2013,100(2):341-8. 被引量:1
  • 5Hajishafiha M,Dehghan M,Kiarang N, et al. Combinedletrozole and clomiphene versus letrozole and clomiphenealone in infertile patients with polycystic ovary syndrome.Drug Des Devel Ther, 2013, 7:1427-31. 被引量:1
  • 6Sovino H, Petermann T,Devoto L. Clomiphene citrate andovulation induction. Reprod Biomed Online, 2002, 4(3):303-10. 被引量:1
  • 7Clark JH, Markaverich BM. The agonistic-antagonistic prop-erties of clomiphene: a review. Pharmacol Ther, 1982,15(3):467-519. 被引量:1
  • 8Dickey RP, Olai* TT,Taylor SN, et al. Relationship of? endometrial thickness and pattern to fecundity in ovulationinduction cycles: effect of clomiphene citrate alone and withhuman menopausal gonadotropin. Fertil Steril, 1993, 59(4):756-60. 被引量:1
  • 9Brueggemeier RW. Update on the use of aromatase inhibitorsin breast cancer. Expert Opin Pharmacother, 2006,7(14):2000-11. 被引量:1
  • 10Mitwally MF, Casper RF. Aromatase inhibitors in ovulationinduction. Semin Reprod Med, 2004,22(1):61-78. 被引量:1

共引文献247

同被引文献95

引证文献10

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部